Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERT trial of tezepelumab for airway remodeling in severe asthma
2024-513195-18-00Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in severe asthma comparing Tezspire with Matching placebo (2 arms). Primary endpoint: Change in mean percentage bronchial wall area. Started Jul 2024; status: completed.
02
Drugs
03
Conditions
severe asthma
Beyond the preview
Go deeper on 2024-513195-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513195-18-00.